vs
ADMA BIOLOGICS, INC.（ADMA）与Aligos Therapeutics, Inc.（ALGS）财务数据对比。点击上方公司名可切换其他公司
ADMA BIOLOGICS, INC.的季度营收约是Aligos Therapeutics, Inc.的823.4倍（$139.2M vs $169.0K）。ADMA BIOLOGICS, INC.净利率更高（35.5% vs -11763.9%，领先11799.4%）。ADMA BIOLOGICS, INC.同比增速更快（18.4% vs -72.1%）。过去两年ADMA BIOLOGICS, INC.的营收复合增速更高（30.4% vs -50.7%）
ADMA生物制剂公司是一家专注于研发、生产及商业化特种血浆来源免疫球蛋白疗法的生物制药企业，主要面向美国市场，为原发性免疫缺陷及其他免疫相关疾病患者、医护人员和医疗机构提供免疫健康领域的治疗方案。
Aligos Therapeutics是一家临床阶段生物制药企业，专注于开发针对流行性肝病与病毒感染的新型靶向疗法，核心管线覆盖慢性乙型肝炎、非酒精性脂肪性肝炎等适应症，通过自主研发推进药物落地，满足全球未被满足的医疗需求。
ADMA vs ALGS — 直观对比
营收规模更大
ADMA
是对方的823.4倍
$169.0K
营收增速更快
ADMA
高出90.5%
-72.1%
净利率更高
ADMA
高出11799.4%
-11763.9%
两年增速更快
ADMA
近两年复合增速
-50.7%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $139.2M | $169.0K |
| 净利润 | $49.4M | $-19.9M |
| 毛利率 | 63.8% | — |
| 营业利润率 | 45.1% | -12907.7% |
| 净利率 | 35.5% | -11763.9% |
| 营收同比 | 18.4% | -72.1% |
| 净利润同比 | -55.9% | 75.8% |
| 每股收益（稀释后） | $0.20 | $4.23 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ADMAALGS
| Q4 25 | $139.2M | $169.0K | ||
| Q3 25 | $134.2M | $741.0K | ||
| Q2 25 | $122.0M | $965.0K | ||
| Q1 25 | $114.8M | $311.0K | ||
| Q4 24 | $117.5M | $606.0K | ||
| Q3 24 | $119.8M | $1.3M | ||
| Q2 24 | $107.2M | $1.1M | ||
| Q1 24 | $81.9M | $694.0K |
净利润ADMAALGS
| Q4 25 | $49.4M | $-19.9M | ||
| Q3 25 | $36.4M | $-31.5M | ||
| Q2 25 | $34.2M | $-15.9M | ||
| Q1 25 | $26.9M | $43.1M | ||
| Q4 24 | $111.9M | $-82.2M | ||
| Q3 24 | $35.9M | $-19.3M | ||
| Q2 24 | $32.1M | $5.1M | ||
| Q1 24 | $17.8M | $-34.9M |
毛利率ADMAALGS
| Q4 25 | 63.8% | — | ||
| Q3 25 | 56.3% | — | ||
| Q2 25 | 55.1% | — | ||
| Q1 25 | 53.2% | — | ||
| Q4 24 | 53.9% | — | ||
| Q3 24 | 49.8% | — | ||
| Q2 24 | 53.6% | — | ||
| Q1 24 | 47.8% | — |
营业利润率ADMAALGS
| Q4 25 | 45.1% | -12907.7% | ||
| Q3 25 | 38.0% | -3827.4% | ||
| Q2 25 | 35.1% | -1924.0% | ||
| Q1 25 | 30.4% | -6187.5% | ||
| Q4 24 | 32.6% | -3393.2% | ||
| Q3 24 | 33.1% | -1610.5% | ||
| Q2 24 | 36.6% | -2489.5% | ||
| Q1 24 | 26.7% | -3176.7% |
净利率ADMAALGS
| Q4 25 | 35.5% | -11763.9% | ||
| Q3 25 | 27.1% | -4256.0% | ||
| Q2 25 | 28.1% | -1643.8% | ||
| Q1 25 | 23.4% | 13854.7% | ||
| Q4 24 | 95.2% | -13556.1% | ||
| Q3 24 | 30.0% | -1540.7% | ||
| Q2 24 | 29.9% | 477.0% | ||
| Q1 24 | 21.7% | -5023.5% |
每股收益（稀释后）ADMAALGS
| Q4 25 | $0.20 | $4.23 | ||
| Q3 25 | $0.15 | $-3.04 | ||
| Q2 25 | $0.14 | $-1.53 | ||
| Q1 25 | $0.11 | $-2.11 | ||
| Q4 24 | $0.45 | $-13.10 | ||
| Q3 24 | $0.15 | $-3.07 | ||
| Q2 24 | $0.13 | $0.81 | ||
| Q1 24 | $0.08 | $-5.58 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $87.6M | $77.8M |
| 总债务越低越好 | $72.1M | — |
| 股东权益账面价值 | $477.3M | $53.5M |
| 总资产 | $624.2M | $88.5M |
| 负债/权益比越低杠杆越低 | 0.15× | — |
8季度趋势，按日历期对齐
现金及短期投资ADMAALGS
| Q4 25 | $87.6M | $77.8M | ||
| Q3 25 | $61.4M | $99.1M | ||
| Q2 25 | $90.3M | $122.9M | ||
| Q1 25 | $71.6M | $137.9M | ||
| Q4 24 | $103.1M | $56.9M | ||
| Q3 24 | $86.7M | $74.9M | ||
| Q2 24 | $88.2M | $94.5M | ||
| Q1 24 | $45.3M | $112.7M |
总债务ADMAALGS
| Q4 25 | $72.1M | — | ||
| Q3 25 | $72.4M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $72.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ADMAALGS
| Q4 25 | $477.3M | $53.5M | ||
| Q3 25 | $431.2M | $71.8M | ||
| Q2 25 | $398.3M | $101.9M | ||
| Q1 25 | $373.4M | $116.4M | ||
| Q4 24 | $349.0M | $-29.0M | ||
| Q3 24 | $231.9M | $50.1M | ||
| Q2 24 | $188.3M | $67.2M | ||
| Q1 24 | $153.7M | $59.8M |
总资产ADMAALGS
| Q4 25 | $624.2M | $88.5M | ||
| Q3 25 | $568.7M | $109.8M | ||
| Q2 25 | $558.4M | $134.7M | ||
| Q1 25 | $510.6M | $150.7M | ||
| Q4 24 | $488.7M | $70.1M | ||
| Q3 24 | $390.6M | $88.4M | ||
| Q2 24 | $376.4M | $108.8M | ||
| Q1 24 | $350.9M | $127.9M |
负债/权益比ADMAALGS
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $35.6M | $-21.7M |
| 自由现金流经营现金流 - 资本支出 | $34.6M | — |
| 自由现金流率自由现金流/营收 | 24.8% | — |
| 资本支出强度资本支出/营收 | 0.8% | — |
| 现金转化率经营现金流/净利润 | 0.72× | — |
| 过去12个月自由现金流最近4个季度 | $27.8M | — |
8季度趋势，按日历期对齐
经营现金流ADMAALGS
| Q4 25 | $35.6M | $-21.7M | ||
| Q3 25 | $13.3M | $-24.3M | ||
| Q2 25 | $21.1M | $-15.5M | ||
| Q1 25 | $-19.7M | $-20.9M | ||
| Q4 24 | $50.2M | $-18.4M | ||
| Q3 24 | $25.0M | $-20.1M | ||
| Q2 24 | $45.6M | $-19.5M | ||
| Q1 24 | $-2.2M | $-22.7M |
自由现金流ADMAALGS
| Q4 25 | $34.6M | — | ||
| Q3 25 | $-1.1M | — | ||
| Q2 25 | $18.7M | — | ||
| Q1 25 | $-24.4M | — | ||
| Q4 24 | $47.5M | — | ||
| Q3 24 | $24.0M | — | ||
| Q2 24 | $43.6M | — | ||
| Q1 24 | $-4.6M | — |
自由现金流率ADMAALGS
| Q4 25 | 24.8% | — | ||
| Q3 25 | -0.8% | — | ||
| Q2 25 | 15.3% | — | ||
| Q1 25 | -21.2% | — | ||
| Q4 24 | 40.4% | — | ||
| Q3 24 | 20.0% | — | ||
| Q2 24 | 40.7% | — | ||
| Q1 24 | -5.6% | — |
资本支出强度ADMAALGS
| Q4 25 | 0.8% | — | ||
| Q3 25 | 10.7% | — | ||
| Q2 25 | 2.0% | — | ||
| Q1 25 | 4.1% | — | ||
| Q4 24 | 2.3% | — | ||
| Q3 24 | 0.9% | — | ||
| Q2 24 | 1.9% | — | ||
| Q1 24 | 2.9% | — |
现金转化率ADMAALGS
| Q4 25 | 0.72× | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.62× | — | ||
| Q1 25 | -0.73× | -0.49× | ||
| Q4 24 | 0.45× | — | ||
| Q3 24 | 0.70× | — | ||
| Q2 24 | 1.42× | -3.85× | ||
| Q1 24 | -0.12× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
